Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

 Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Shots:

  • Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the trial
  • The focus of the agreement is to discover targets and develop treatments, with combined techniques of the company in pulmonary disorders including idiopathic pulmonary fibrosis (IPF)
  • In 2014, Bayer and Kyoto University’s Office of Society-Academia Collaboration for Innovation (KU-SACI) collaborated to jointly explore candidates for certain research projects in areas cardiology & oncology including hematology, gynecology, and ophthalmology

Click here to read full press release/ article | Ref: Bayer | Image: Bayer